May 22, 2023 11:06 AM EDTUpdated 12:42 PM
Financing
Startups

Chas­ing the KRAS field, Quan­ta Ther­a­peu­tics bags $50M for two 2024 clin­i­cal tri­als

Kyle LaHucik

Senior Reporter

Quan­ta Ther­a­peu­tics will bring its KRAS in­hibitors in­to the clin­ic next year with a fresh heap of $50.7 mil­lion from blue …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Executive Director, Marketing

Celldex Therapeutics

Hampton, NJ, USA

TRENDING NOW

Boehringer’s up­dat­ed re­sults in HER2-mu­tat­ed lung can­cer im­press

No­vavax re­sponds to FDA’s tri­al ask, with Covid vac­cine strain up­dates un­der scruti­ny

GSK’s check­point block­er Jem­per­li cures bio­mark­er-dri­ven rec­tal can­cer

Mer­ck KGaA to buy rare can­cer biotech Spring­Works for $3.9B

Eu­ro­pean reg­u­la­tors rec­om­mend new drugs from Ver­tex, Am­gen and Jazz 

sponsored

Rev­o­lu­tion­iz­ing obe­si­ty treat­ment: Could mi­to­chon­dria hold the key to un­lock­ing fat-spe­cif­ic weight loss?

A service from the Financial Times